HYDERABAD, India I June 18, 2014 I The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product in India, darbepoetin alfa. This launch marks a significant advancement for Hetero in a biosimilars market expected to grow to US$ 24B in the next five years. In partnership with several prominent pharmaceutical companies, Hetero is launching the drug across India.
Darbepoetin alfa is a synthetic form of erythropoietin, clinically proven to stimulate erythropoiesis (increased hemoglobin levels) for patients with anemia due to chronic kidney disease. With India’s age-adjusted incidence rate of 229 per million population and over 100,000 new patients who enter renal replacement programs annually, chronic kidney disease is a rapidly growing issue in India according to BMC Nephrology. This presents a tremendous opportunity for Hetero and its partners.
Dr. BPS Reddy, Hetero Group’s Chairman and founder, noted, “Hetero’s launch of this biosimilar in India demonstrates both our leadership in new biopharmaceutical technologies, and our commitment to improving patient treatment options. Less than five years ago, Hetero first launched its biosimilar effort by building a state of the art R&D and manufacturing facility in Jedcherla, near Hyderabad. For the large number of patients undergoing regular dialysis treatment, darbepoetin alfa’s efficacy and safety, coupled with its once weekly dosing are expected to contribute to improved compliance rates and therapeutic outcomes. We look forward to continued collaboration with our commercial partners as we bring the darbepoetin alfa biosimilar to the service of physicians and patients.”
Hetero’s launch of darbepoetin alfa in India marks a milestone in its strategy to penetrate the complex biosimilars market.
ABOUT HETERO
Hetero is a leading global developer, manufacturer, and marketer of pharmaceuticals and their active ingredients. It is the largest privately-owned pharmaceutical company in India. Founded in 1993, Hetero maintains 20 manufacturing facilities across the globe and markets a portfolio of over 200 products in 138 countries. Hetero’s commitment to reliability, quality, and value have been a cornerstone since its inception, and the company offers a unique value proposition to its customers in its ability to create efficiencies through vertical integration across the entire manufacturing process.
SOURCE: Hetero
Post Views: 221
HYDERABAD, India I June 18, 2014 I The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product in India, darbepoetin alfa. This launch marks a significant advancement for Hetero in a biosimilars market expected to grow to US$ 24B in the next five years. In partnership with several prominent pharmaceutical companies, Hetero is launching the drug across India.
Darbepoetin alfa is a synthetic form of erythropoietin, clinically proven to stimulate erythropoiesis (increased hemoglobin levels) for patients with anemia due to chronic kidney disease. With India’s age-adjusted incidence rate of 229 per million population and over 100,000 new patients who enter renal replacement programs annually, chronic kidney disease is a rapidly growing issue in India according to BMC Nephrology. This presents a tremendous opportunity for Hetero and its partners.
Dr. BPS Reddy, Hetero Group’s Chairman and founder, noted, “Hetero’s launch of this biosimilar in India demonstrates both our leadership in new biopharmaceutical technologies, and our commitment to improving patient treatment options. Less than five years ago, Hetero first launched its biosimilar effort by building a state of the art R&D and manufacturing facility in Jedcherla, near Hyderabad. For the large number of patients undergoing regular dialysis treatment, darbepoetin alfa’s efficacy and safety, coupled with its once weekly dosing are expected to contribute to improved compliance rates and therapeutic outcomes. We look forward to continued collaboration with our commercial partners as we bring the darbepoetin alfa biosimilar to the service of physicians and patients.”
Hetero’s launch of darbepoetin alfa in India marks a milestone in its strategy to penetrate the complex biosimilars market.
ABOUT HETERO
Hetero is a leading global developer, manufacturer, and marketer of pharmaceuticals and their active ingredients. It is the largest privately-owned pharmaceutical company in India. Founded in 1993, Hetero maintains 20 manufacturing facilities across the globe and markets a portfolio of over 200 products in 138 countries. Hetero’s commitment to reliability, quality, and value have been a cornerstone since its inception, and the company offers a unique value proposition to its customers in its ability to create efficiencies through vertical integration across the entire manufacturing process.
SOURCE: Hetero
Post Views: 221
